E
Enliven Therapeutics, Inc. (ELVN)
NMS – Real Time Price. Currency in USD
42.30
+2.71 (6.85%)
At close: May 12, 2026, 4:00 PM EDT
42.36
+0.06 (0.14%)
Pre-market: May 13, 2026, 5:50 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
42.30
+2.71 (6.85%)
At close: May 12, 2026, 4:00 PM EDT
42.36
+0.06 (0.14%)
Pre-market: May 13, 2026, 5:50 AM EDT
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
| Name | Position |
|---|---|
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development |
| Mr. Richard A. Fair M.B.A. | CEO, President & Director |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder & Head of Pipeline |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | elvn-20260507.htm |
| 2026-05-07 | 10-Q | elvn-20260331.htm |
| 2026-04-27 | DEFA14A | d948532ddefa14a.htm |
| 2026-04-15 | PRE 14A | d948512dpre14a.htm |
| 2026-03-03 | S-8 | d189577ds8.htm |
| 2026-01-07 | 8-K | d28332d8k.htm |
| 2025-12-16 | S-8 | d63864ds8.htm |
| 2025-12-11 | 8-K | d937094d8k.htm |
| 2025-11-13 | 8-K/A | elvn-20251112.htm |
| 2025-11-12 | 10-Q | elvn-20250930.htm |